433 related articles for article (PubMed ID: 31272342)
1. Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives.
Kaštelan S; Antunica AG; Oresković LB; Pelčić G; Kasun E; Hat K
Curr Med Chem; 2020; 27(8):1350-1366. PubMed ID: 31272342
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
3. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
[TBL] [Abstract][Full Text] [Related]
4. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
[TBL] [Abstract][Full Text] [Related]
5. Liver metastasis in uveal melanoma - treatment options and clinical outcome.
Kaštelan S; Mrazovac Zimak D; Ivanković M; Marković I; Gverović Antunica A
Front Biosci (Landmark Ed); 2022 Feb; 27(2):72. PubMed ID: 35227015
[TBL] [Abstract][Full Text] [Related]
6. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility.
Leonard-Murali S; Bhaskarla C; Yadav GS; Maurya SK; Galiveti CR; Tobin JA; Kann RJ; Ashwat E; Murphy PS; Chakka AB; Soman V; Cantalupo PG; Zhuo X; Vyas G; Kozak DL; Kelly LM; Smith E; Chandran UR; Hsu YS; Kammula US
Nat Commun; 2024 Apr; 15(1):2863. PubMed ID: 38627362
[TBL] [Abstract][Full Text] [Related]
7. Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.
Goh AY; Layton CJ
Clin Exp Ophthalmol; 2016 Aug; 44(6):509-19. PubMed ID: 26601795
[TBL] [Abstract][Full Text] [Related]
8. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
[TBL] [Abstract][Full Text] [Related]
9. The treatment of metastatic uveal melanoma.
Pyrhönen S
Eur J Cancer; 1998 Jul; 34 Suppl 3():S27-30. PubMed ID: 9849406
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of uveal melanoma.
Bosch JJ
Dev Ophthalmol; 2012; 49():137-149. PubMed ID: 22042018
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
12. Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?
Sacco JJ; Kalirai H; Kenyani J; Figueiredo CR; Coulson JM; Coupland SE
Future Oncol; 2018 Jun; 14(14):1335-1338. PubMed ID: 29741103
[No Abstract] [Full Text] [Related]
13. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.
Javed A; Arguello D; Johnston C; Gatalica Z; Terai M; Weight RM; Orloff M; Mastrangelo MJ; Sato T
Immunotherapy; 2017 Dec; 9(16):1323-1330. PubMed ID: 29185395
[TBL] [Abstract][Full Text] [Related]
14. Uveal melanoma: physiopathology and new in situ-specific therapies.
Souto EB; Zielinska A; Luis M; Carbone C; Martins-Gomes C; Souto SB; Silva AM
Cancer Chemother Pharmacol; 2019 Jul; 84(1):15-32. PubMed ID: 31079217
[TBL] [Abstract][Full Text] [Related]
15. Identification of molecular subtyping system and four-gene prognostic signature with immune-related genes for uveal melanoma.
Xia F; Yu Z; Deng A; Gao G
Exp Biol Med (Maywood); 2022 Feb; 247(3):246-262. PubMed ID: 34743576
[TBL] [Abstract][Full Text] [Related]
16. Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma.
Lane AM; Kim IK; Gragoudas ES
JAMA Ophthalmol; 2018 Sep; 136(9):981-986. PubMed ID: 29955797
[TBL] [Abstract][Full Text] [Related]
17. Determinants of overall survival in patients with metastatic uveal melanoma.
Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
[TBL] [Abstract][Full Text] [Related]
18. Update on Metastatic Uveal Melanoma: Progress and Challenges.
Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Uveal Melanoma.
Shoushtari AN; Carvajal RD
Cancer Treat Res; 2016; 167():281-93. PubMed ID: 26601868
[TBL] [Abstract][Full Text] [Related]
20. Effect of anti-ganglioside antibodies on the metastatic spread of intraocular melanomas in a nude mouse model of human uveal melanoma.
Niederkorn JY; Mellon J; Pidherney M; Mayhew E; Anand R
Curr Eye Res; 1993 Apr; 12(4):347-58. PubMed ID: 8319494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
